ADNI » Genetics Core

New ADNIGO-2 ApoE Genotype information available.

idossantos — Wed, 15 May 2013 01:28:12 +0000

New ADNI GO & 2 ApoE Genotypes are available in the Download section of the ADNI archive.

The dataset can be found under Biospecimen, Biospecimen Results.

ADNI GO/2 GWAS Data Available

kcrawford — Thu, 19 Jul 2012 21:53:39 +0000

The ADNI Genetics Core has released GWAS data for ADNI GO/2 participants which is now available from the download section. Due to the large volume of data, the 432 individual subject files have been compressed into 9 zip files. Please note that the new GWAS uses an updated chip so the new data do not exactly match earlier ADNI 1 files.

GWAS Data – Plink version

kcrawford — Thu, 12 Jul 2012 17:13:15 +0000

The Plink version of ADNI 1 GWAS data is now available in the Download section of the IDA.

ADNI GO & 2 ApoE data available

idossantos — Tue, 05 Jun 2012 22:04:33 +0000

Updated ApoE information for 96 ADNI GO and ADNI 2 subjects is now available from the DOWNLOAD section of the ADNI archive.

ADNI 2 APOE Genotype Results Notification

blee — Wed, 23 May 2012 23:27:53 +0000

One of samples included in the ADNI 2 APOE genotyping results may have been mislabeled and has been removed from the dataset. Those who downloaded the APOE results between January 25, 2012 and May 23,2012 should not use the results for the row containing RID=4014. New results for this subject will be posted after re-analysis.

ADNI biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.

blee — Thu, 20 May 2010 22:40:20 +0000

Abstract: The role of the Alzheimer’s Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer’s Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer’s disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.

Authors: Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Risacher SL, Nho K, Huentelman MJ, Craig DW, Thompson PM, Stein JL, Moore JH, Farrer LA, Green RC, Bertram L, Jack CR Jr, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):265-73.

See this article in Pubmed